Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
NBOH-2C-CN hydrochloride is a high affinity, selective 5-HT2A agonist (Ki = 1.3 nM). Exhibits 100-fold selectivity for 5-HT2A over 5-HT2C. Elicits head twitch behavior in mice.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||3.49||10 with gentle warming|
The following data is based on the product molecular weight 348.82. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.87 mL||14.33 mL||28.67 mL|
|5 mM||0.57 mL||2.87 mL||5.73 mL|
|10 mM||0.29 mL||1.43 mL||2.87 mL|
|50 mM||0.06 mL||0.29 mL||0.57 mL|
References are publications that support the biological activity of the product.
Hansen et al (2014) Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS.Chem.Neurosci. 5 243 PMID: 24397362
Fantegrossi et al (2014) Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice. Psychopharmacology (Berl.) 232 1039 PMID: 25224567
Jensen et al (2017) Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. J.Pharmacol.Exp.Ther 361 441 PMID: 28360333
Jensen et al (2020) The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [ 3H]25CN-NBOH. Biochem.Pharmacol. 177 113979 PMID: 32298690
If you know of a relevant reference for NBOH-2C-CN hydrochloride, please let us know.
Keywords: NBOH-2C-CN hydrochloride, NBOH-2C-CN hydrochloride supplier, serotonin, potent, selective, high, affinity, 5-ht, 5-ht2a, agonists, receptors, hallucinogen-like, 25CN-NBOH, 5-HT2A, Receptors, 5171, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for NBOH-2C-CN hydrochloride. Do you know of a great paper that uses NBOH-2C-CN hydrochloride from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review NBOH-2C-CN hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.